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Abstract 
Background:  The present study investigated how much Swiss general internal medicine practitioners (GPs) know 
about new direct oral anticoagulants (NOACs), particularly the relevant guidelines, follow-up tests, dosing adjust-
ments, indications and complications. We conducted a paper-based survey of GPs, performed in Bern, Switzerland. 
Our questionnaire assessed the physicians’ preference for NOACs rather than vitamin K antagonists (VKA), prevalence 
and choice of NOAC, clinical follow-up including follow-up blood testing, and bleeding complications.
Results: 53 GPs participated in our pilot investigation. They treated 32.7% ± 19 of their patients requiring oral antico-
agulation with NOACs. New patients who had started oral anticoagulation received NOACs from 49 GPs (92.5%) but 
most GPs would not switch patients from existing VKA therapy to NOACs. Clinical controls are scheduled by a major-
ity of GPs (67.9%) at least every 3 months; creatinine and haemoglobin are monitored by most GPs (51 (96.2%) and 
39 (73.6%), respectively). In the preceding 2 years, GPs had seen 1.9 ± 2.87 bleeding complications in patients with 
NOACs. 0.5 ± 0.95 (range 0–5) of these required hospital treatment.
Conclusion: NOACs are broadly accepted by investigated Swiss GPs as the first choice for patients newly requiring 
oral anticoagulation. This was in preference to VKAs and especially if recommended by a haematologist or cardiolo-
gist. As, in our population, only about two-thirds of GPs adhere to recommendations on clinical and blood test follow-
ups, further efforts to implement follow-up guidelines seem necessary. Further research in a large representative GP 
population is recommended; this should compare NOACs and VKAs. Bleeding complications were rare in our popula-
tion and could mostly be handled without hospital admission.
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Background
New direct oral anticoagulants (NOACs) have been 
introduced in recent years and this type of oral antico-
agulation is of increasing importance in everyday clinical 
work, in both emergency departments (EDs) and general 
practice. In addition to the studies for initial approval, 
plenty of data have been published on the safety and effi-
cacy of NOACs (Connolly et al. 2009; Granger et al. 2011; 
Patel et al. 2011). On the other hand, few studies report 
on the use of these drugs in hospitals or general practices.
Lee et al. (2012) assessed the representativeness of the 
registration studies RE-LY, ARISTOTLE and ROCKET-
AF and concluded that they were not equally representa-
tive of the real-life UK population with atrial fibrillation. 
Such problems with trial generalizability are recognised 
and have to be taken into account when trying to transfer 
trial results into general practice (Weiss et al. 2008).
In a preliminary study, Southworth et  al. (2013) com-
pared patients on dabigatran with those on warfarin 
and found similar incidences of gastrointestinal and 
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intracerebral bleeding events. Recent observational data 
from our university emergency department have con-
firmed the low incidence of serious bleeding events. We 
found that epistaxis, haematomas and gastrointestinal 
bleeding are the most frequent bleeding complications 
under the new drugs (Sauter et al. 2016).
Further real life observational data—external valida-
tion rather than registration studies—are essential, as 
adherence to guidelines in everyday practice is unclear 
with respect to follow-up tests, dosing adjustments and 
indications. It might e.g. be speculated that patients with 
NOACS gain less attention in follow-up than do patients 
on vitamin K antagonists (VKAs), as INR testing is not 
required for NOACs. A recent investigation of the pre-
scription and use of NOACs in the USA showed that 39% 
of all patients received an inappropriate dose of NOACs. 
Moreover, 6% of patients reported that they missed about 
one dose each week (Simon et al. 2015).
We therefore aimed to investigate the real-life handling 
and complications of patients treated with NOACs, as 
encountered in everyday general practice and as influ-
enced by general internal medicine practitioners’ (GPs’) 
awareness of NOAC therapy and follow-up guidelines.
Methods
We conducted a paper-based survey of GPs attending a GP 
emergency medicine congress at Inselspital, Bern Univer-
sity Hospital, Switzerland. Demographic data on age, gen-
der, speciality and professional experience were collected.
Our questionnaire consisted of four topics (Question-
naire is available on request.):
  • We asked GPs whether they preferred NOACs to 
VKAs and, if so, why. We also inquired how many 
of their patients were on NOACs in comparison to 
VKAs and whether the GPs switched from VKAs to 
NOACs for anticoagulation.
  • We examined the choice of a NOAC and the reason 
for this selection.
  • We recorded the frequency of clinical follow-up vis-
its, as well as the frequency and type of follow-up 
blood-testing for patients treated with NOACs.
  • We assessed the frequency of bleeding complica-
tions encountered in general practices in the pre-
ceding two years, as well as the type and localisation 
of bleeding complications and the need for hospital 
admission.
All questionnaires were anonymised before analysis. 
All participating GPs gave their written consent for the 
analysis and publication of collected data.
As no individual patient data are acquired in our sur-
vey, no ethical approval is necessary.
We performed all statistical calculations with SPSS Sta-
tistics 21 (IBM Corp.) and used descriptive statistics as 
appropriate.
Results
Demographic characteristics
53 GPs participated in our survey (response rate 
40.8%). The mean age was 49.3  ±  10.8  years (SD, 
range 28–67  years) with a working experience of 
13.7 ± 11.3 years (range 1–40 years). 26 GPs were female 
(49.1%) and 27 male (50.9%). Four GPs had no special-
ity (7.5%); 49 (92.5%) were specialists in general internal 
medicine. In Switzerland, after successfully completing 
general practitioner training, the title “FMH Allgemeine 
Innere Medizin” (specialist in general internal medicine) 
is awarded.
NOACs versus VKAs
New patients who were started on oral anticoagulation 
received NOACs and not VKAs from 49 GPs (92.5%), 
unless there were contraindications or patient prefer-
ences that were independent of the indication for antico-
agulation. The preference for the prescription of NOACs 
in comparison to VKAs are shown in Table  1 for spe-
cific indications. The reasons for starting directly with 
NOACs are listed in Table  2. All GPs included in our 
survey treat patients with NOACs (n =  53). Altogether 
GPs in our survey treated 32.7% ± 19.0 (range 10–80%) 
of their patients on oral anticoagulation with NOACs. 
Table 1 Preference for NOACS to VKA by indication
n = 53. Multiple answers possible. Absolute number (%)
PE pulmonary embolism, DVT deep venous thrombosis
Indication Number (%)
Prevention of recurrent PE/DVT 43 (81.1%)
Treatment of PE/DVT 42 (79.2%)
Prophylactic post-surgery 39 (73.6%)
Atrial fibrillation 37 (69.8%)
Table 2 Reasons for  direct start with  NOACs instead 
of VKAs
Multiple answers possible. n = 53. Absolute number (%)
Reasons Number (%)
Easier dosing 51 (96.2%)
Fewer blood tests 48 (90.6%)
Fewer clinical follow-ups 33 (62.3%)
Fewer bleeding events 24 (45.3%)
Age of patients 20 (37.7%)
Better tolerance 5 (9.4%)
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In patients already under therapy with VKAs, 14 GPs 
(26.4%) would decide to switch to any NOAC. Eight GPs 
(15.1%) indicated that they were not prepared to switch 
stable patients and five GPs (9.4%) would not switch 
because of the higher costs of NOACs.
NOAC preference
Rivaroxaban is the NOAC prescribed by most GPs 
(75.5%). In general, 52 GPs (98.1%) prescribed rivar-
oxaban, 8 apixaban (15.1%), 6 dabigatran (11.3%) and 3 
edoxaban (5.6%). The reasons for these preferences are 
shown in Table 3.
Follow‑up of NOAC
The frequency of clinical follow-up consultations and 
follow-up blood tests of patients with NOACs are 
reported in Table  4. Clinical controls are scheduled by 
36 of the GPs (67.9%) at least every 3  months. Creati-
nine and haemoglobin are laboratory parameters moni-
tored by the majority of GPs (51 (96.2%) and 39 (73.6%), 
respectively).
Bleeding complications
In the preceding 2 years, GPs had seen 1.9 ± 2.87 (range 
0–14) bleeding complications in patients with NOACs in 
their practice. For details of the bleeding complications 
in patients with NOACs, see Table  5. The GPs had to 
refer 0.5 ± 0.95 (range 0–5) of these patients to hospital 
treatment.
Discussion
In the present study, we aimed to analyse everyday use 
and experiences with NOACs in general practise.
NOACs versus VKAs
The growing importance of NOACs is broadly reflected 
in the daily practice of Swiss GPs surveyed in our inves-
tigation. Nearly all new patients with a new indication 
for oral anticoagulation are started on NOACs, although 
international guidelines differ. In contrast to the guide-
lines from the European Society of Cardiology (ECS), 
the American Heart Association (AHA) guideline for 
the management of patients with AF still recommends 
VKAs rather than NOACs (January et  al. 2014; Camm 
et al. 2012).
It is striking that “atrial fibrillation” (AF)—the indica-
tion for which NOACS were first approved—is the least 
preferred indication in our dataset. In venous throm-
bosis, NOACs are more broadly accepted by the GPs 
in our survey, although the corresponding guideline by 
the ESC gives no specific recommendation (Konstan-
tinides et  al. 2014). To facilitate the choice between 
NOACs and VKAs in the future, GPs have the possibil-
ity of using newer decision tools like the SAMe-TT2R2 
score to predict poor INR outcome (Proietti and Lip 
2015).
In contrast to new patients started on oral anticoagula-
tion, existing therapy with VKAs was mostly continued 
in our population. This is consistent with the recommen-
dations in the AHA guidelines not to switch stable and 
satisfied patients on easily controlled VKA therapy (Janu-
ary et al. 2014).
NOAC preference
Because no head-to-head trials of NOACs exist, there 
are no clear recommendations for the choice of a spe-
cific NOAC. By far the most common reason given in our 
Table 3 Reasons for NOAC preference
Multiple answers possible. n = 53. Absolute number (%)
Reasons Number (%)
Prescription by specialists 37 (69.8%)
Evidence 27 (50.9%)
Prevalence 25 (47.2%)
Patient’s profile 13 (30.2%)
Easier dosing OD 9 (17.0%)
Patient’s choice 7 (13.2%)
Personal experience 3 (5.7%)
Table 4 Frequency of clinical follow-up consultations and blood tests of patients treated with NOACs
n = 53
INR International normalised ratio
Frequency Clinical Creatinine INR Liver enzymes Haemoglobin
Never 2 (3.8%) 2 (3.8%) 46 (86.8%) 21 (39.6%) 14 (26.4%)
Once 0 (0%) 3 (5.7%) 3 (5.7%) 2 (3.8%) 3 (5.7%)
Monthly 1 (1.9%) 2 (3.8%) 0 (0%) 2 (3.8%) 2 (3.8%)
Every 2–3 months 35 (66%) 17 (31.2%) 1 (1.9%) 4 (7.5%) 11 (20.8%)
Every 6 months 13 (24.5%) 21 (39.6%) 0 (0%) 10 (18.8%) 15 (28.3%)
Annually 2 (3.8%) 8 (15.1%) 3 (5.7%) 14 (26.4%) 8 (15.1%)
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survey was a pre-existing prescription by a specialist or 
hospital.
Follow‑up of patients with NOAC
About two-thirds of GPs clinically monitor their patients 
on NOACs at least every 3  months, even though INR 
testing is no longer necessary, as it is for patients under 
VKAs. This complies with the only guideline available at 
the moment: the practical guideline from the European 
Heart Rhythm Association (EHRA). This guideline rec-
ommends clinical follow-ups initially after 1 month and 
later every third month (Heidbuchel et  al. 2015). About 
the same percentage of GPs follow the recommenda-
tions for blood tests: The EHRA guideline recommends 
annual haemoglobin and liver enzyme controls. The rec-
ommendation for creatinine controls depend on renal 
function and we did not differentiate this in our ques-
tionnaire. In general, creatinine is checked by the GPs in 
our survey more frequently than other blood parameters, 
as requested in the EHRA guideline. This is reassuring, 
giving the fact that in an American survey Simon et  al. 
(2015) found that creatinine was not measured in about 
40% of patients, not even at the time of prescription.
However, given the potentially dangerous complica-
tions in patients on oral anticoagulation, an overall adher-
ence rate to current follow-up guidelines of only about 
two-thirds seems suboptimal and should prompt further 
research and would need improvement. This might also 
include a comparison of real-life follow-up consultations 
and blood tests in NOAC versus VKA patients.
Bleeding events
The type of bleeding complications and the ratio of minor 
to major bleeding events seen in our survey matches 
the results of a previous study of our ED patients (Sau-
ter et al. 2016). Minor bleeding complications (epistaxis, 
haematoma) were encountered about every second year 
by a GP, and major bleeding complications (gastrointes-
tinal bleeding, intracranial or abdominal bleeding) about 
every fourth year. Furthermore, very few patients have 
to be referred to a hospital because of bleeding com-
plications. It is important to keep in mind that patients 
with major bleeding may present directly to hospi-
tal emergency departments and may not consult their 
GP. Therefore the absolute number of major bleeding 
events is likely to be underestimated by the GPs. The 
hospitalisation rate seems especially important for the 
comparison of costs in NOACs versus VKAs, as hospi-
talisation because of a bleeding event is a major cost fac-
tor (Kim et al. 2010; Ghate et al. 2011). For this purpose, 
a comparison of NOAC versus VKA for GP reported 
bleeding events would also be of interest in follow-up 
investigations.
Limitations
The sample of GPs in our survey is very small and may 
not be representative, because we conducted the survey 
as a pilot study in unselected GPs presenting to a con-
gress. It is conceivable that GPs presenting to an emer-
gency medicine congress are more progressive and 
educated, as well as being more aware of emergency 
medicine and complications than average. We did not 
ask GPs how many patients they cared for and therefore 
cannot calculate a risk per patient in bleeding complica-
tions. Our pilot study demonstrates the areas of knowl-
edge in the handling of NOACs by GPs that need further 
research. In particular, future studies should focus on 
adherence to the guidelines from the European Society of 
Cardiology and the American Heart Association and on 
the control of patients’ adherence to the treatment. This 
first pilot investigation can only provide initial insights 
and might promote awareness of real-life problems and 
stimulate further research.
Conclusions
On the basis of our pilot survey, NOACs seem broadly 
accepted among the investigated Swiss GPs as first 
choice—in preference to VKAs—for patients newly 
requiring oral anticoagulation, especially if recom-
mended by haematologists or cardiologists. Because only 
about two-thirds of GPs in our survey adhere to recom-
mendations on clinical and blood test follow-ups, further 
efforts to implement follow-up guidelines seem neces-
sary, as is further extended research in a large representa-
tive GP population—including a comparison of NOACs 
and VKAs. Bleeding complications reported by our pop-
ulation are rare and were mostly handled in the outpa-
tient setting without hospital admission.
Table 5 Overview of  bleeding complications of  patients 
treated with NOACs
Multiple answers possible. n = 53
Bleeding complications Absolute number/year Number/GP/year
Severity
Minor 31 0.58
Life-threatening 13.5 0.25
Location
Epistaxis 17 0.32
Haematoma 12 0.23
Gastrointestinal bleeding 11.5 0.22
Intracranial bleeding 2 0.04
Abdominal bleeding 0 0
Other 2 0.04
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